Tag: pharmaceuticals

  • Sanofi, Fox Foundation Partner on Parkinson’s Drug Trial

    The drug manufacturer Sanofi, based in Paris, and the Michael J. Fox Foundation in New York agreed today to conduct a clinical trial of AVE8112, a Sanofi compound, in patients with Parkinson’s disease. AVE8112 is a type of anti-inflammatory drug known as PDE4 inhibitors that have been tested as treatments for respiratory diseases, but in…

  • Biotech Company Secures $38 Million Series D Funds

    Alder BioPharmaceuticals Inc. in Bothell, Washington says it closed $38 million in financing today to support clinical studies of its two lead compounds. The series D round, the fourth financing installment after initial start-up, is led by Novo Ventures, the venture capital subsidiary of Danish pharmaceutical maker Novo Nordisk. Alder BioPharmaceuticals has developed an antibody production…

  • Clinical Trial Shows Brain Cancer Vaccine Extends Lives

    A clinical trial involving researchers from University of California at San Francisco and the biotechnology company Agenus Inc. in Lexington, Massachusetts found a vaccine has extended the lives of patients with recurrent glioblastoma multiforme, a type of brain cancer. The findings are being presented today at a meeting of the American Association of Neurological Surgeons.…

  • Nutritional Enzyme Maker Secures $10M Early-Stage Financing

    Alcresta, in Newton, Massachusetts, has closed a $10 million series A financing round, the first funding installment after start-up. Investors are led by the venture capital firms Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures. The company develops and commercializes enzyme-based nutritional products designed to improve the health of and manage disease for infants,…

  • Quarter of Grandparents Keep Meds Where Kids Can Find Them

    A survey by the University of Michigan C.S. Mott Children’s Hospital in Ann Arbor shows nearly one quarter of grandparents in the U.S. of children age 1 to 5 say they keep their prescription medicines in easily accessible containers or locations. The findings were part of the hospital’s National Poll on Children’s Health conducted in…

  • Piramal Healthcare Buys Bayer Molecular Imaging Portfolio

    Piramal Healthcare, a pharmaceutical and drug discovery company in Mumbai, India, says it has acquired rights to the molecular imaging research and development portfolio of Bayer Pharma AG in Leverkusen, Germany. The company has formed a new subsidiary, Piramal Imaging SA, to manage these assets. Financial terms of the sale were not disclosed, but Piramal…

  • Not-For-Profit Hospital Starts $10M Health Care Venture Fund

    Rex Healthcare, a not-for-profit health care system in Raleigh, North Carolina, has unveiled Rex Strategic Innovations that offers funding for start-up companies and organizations, including venture capital financing. The program is also devising ways to help individuals and organizations develop ideas for improving health care into real-life goods and services. The initiative includes Rex Health…

  • AstraZeneca, NGO to Partner on Neglected Tropical Diseases

    The group Drugs for Neglected Diseases initiative (DNDi), a non-government organization in Geneva, and the pharmaceutical company AstraZeneca have agreed to collaborate on drug-compound screening for three neglected tropical diseases. The three diseases — leishmaniasis, Chagas disease, and sleeping sickness — together affect nearly 10 million people worldwide. Under the agreement, AstraZeneca will provide to…

  • PhRMA Company R&D Investment Flat in 2011

    The Pharmaceutical Research and Manufacturers of America (PhRMA) released its annual industry profile today showing its 28 member companies spent $49.5 billion on research and development in 2011, down slightly from the $50.7 billion expended in 2010. The $49.5 billion spent on R&D is about 17 percent of total sales. The organization cites the latest…

  • Biotech Licenses Brain-Nervous System Treatment Technology

    Ben-Gurion University of the Negev in Israel says it has licensed a technology from its labs that crosses the blood-brain barrier to deliver drugs for treating disorders of the brain and central nervous system. The V-Smart technology, as its called, was licensed exclusively to Lauren Sciences LLC, a privately held biotechnology company in New York.…